CD276 and cancer: By comparing CD276-positive cancer cell lines with CRISPR-Cas9-engineered isogenic CD276-KO controls, we verified that target expression is essential for potent (subnanomolar) activity of the m276-SL-PBD ADC, but not for the PBD-free drug SGD1882 (Figure S6).